News


07/30/14, Cancer Stivarga® (regorafenib) from Bayer Approved in the European Union for the Treatment of Gastrointestinal Stromal Tumors Approval in the second indication for Stivarga in the EU within one year / Decision based on positive results from Phase III GRID trial in which regorafenib significantly extended progression-free survival more

"Young people want self-determination": Parliamentary Evening in Berlin

What do young people worldwide wish for the future?

more

Taking the "neglect" out of "Neglected Tropical Diseases":

Two years after the London Declaration, tremendous progress is apparent more

Taking targeted action against tuberculosis

March 24, 2014 is World Tuberculosis Day more

Bayer Clinical Trials

Information about Bayer sponsored clinical studies is available at

Facebook

Facebook Banner

Follow us on Facebook

more

Links


http://www.bayerpharma.com/en/index.php?n=irp

Copyright © Bayer Pharma AG